Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/should-we-take-high-density-lipoprotein-cholesterol-levels-at-face-OnmUTJDwK0
References (27)
-
K. Saku, P. Gartside, B. Hynd, M. Kashyap (1985)
Mechanism of action of gemfibrozil on lipoprotein metabolism.The Journal of clinical investigation, 75 5
-
Karen Kozarsky, M. Donahee, J. Glick, M. Krieger, D. Rader (2000)
Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse.Arteriosclerosis, thrombosis, and vascular biology, 20 3
-
Takeshi Arai, Nan Wang, Mikhail Bezouevski, Carrie Welch, A. Tall (1999)
Decreased Atherosclerosis in Heterozygous Low Density Lipoprotein Receptor-deficient Mice Expressing the Scavenger Receptor BI Transgene*The Journal of Biological Chemistry, 274
-
J. Stockman (2009)
Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trialYearbook of Pediatrics, 2009
-
M. Bots, F. Visseren, G. Evans, W. Riley, J. Revkin, C. Tegeler, C. Shear, W. Duggan, R. Vicari, D. Grobbee, J. Kastelein (2007)
Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trialThe Lancet, 370
-
V. Gualandri, G. Franceschini, C. Sirtori, G. Gianfranceschi, G. Orsini, A. Cerrone, A. Menotti (1985)
AIMilano apoprotein identification of the complete kindred and evidence of a dominant genetic transmission.American journal of human genetics, 37 6
-
T. Gordon, W. Castelli, M. Hjortland, W. Kannel, T. Dawber (1977)
High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study.The American journal of medicine, 62 5
-
S. Leuven, L. Burgess, G. Evans, J. Kuivenhoven, P. Barter, J. Revkin, D. Grobbee, W. Riley, C. Shear, W. Duggan, M. Bots (2007)
Effect of Torcetrapib on Carotid Atherosclerosis in Familial HypercholesterolemiaThe New England Journal of Medicine, 356
-
Y. Ueda, L. Royer, E. Gong, Junli Zhang, P. Cooper, O. Francone, E. Rubin (1999)
Lower Plasma Levels and Accelerated Clearance of High Density Lipoprotein (HDL) and Non-HDL Cholesterol in Scavenger Receptor Class B Type I Transgenic Mice*The Journal of Biological Chemistry, 274
-
I. Yuhanna, Yan Zhu, B. Cox, L. Hahner, S. Osborne-Lawrence, P. Lu, Y. Marcel, R. Anderson, M. Mendelsohn, H. Hobbs, P. Shaul (2001)
High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthaseNature Medicine, 7
-
C. Sirtori, L. Calabresi, G. Franceschini, D. Baldassarre, M. Amato, J. Johansson, M. Salvetti, C. Monteduro, R. Zulli, M. Muiesan, E. Agabiti-Rosei (2001)
Cardiovascular Status of Carriers of the Apolipoprotein A-IMilano Mutant: The Limone sul Garda StudyCirculation: Journal of the American Heart Association, 103
-
M. Forrest, D. Bloomfield, R. Briscoe, P Brown, A. Cumiskey, J. Ehrhart, J. Hershey, W Keller, X. Ma, H McPherson, E. Messina, L Peterson, W. Sharif-Rodriguez, P. Siegl, P Sinclair, C. Sparrow, A Stevenson, S-Y Sun, C. Tsai, H. Vargas, M. Walker, S West, V. White, R. Woltmann (2008)
Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosteroneBritish Journal of Pharmacology, 154
-
P.J. Barter, M. Caulfield, M. Eriksson (2007)
Effects of torcetrapib in patients at high risk for coronary eventsN Engl J Med, 357
-
H. Rubins, S. Robins, M. Iwane, W. Boden, M. Elam, C. Fye, D. Gordon, E. Schaefer, G. Schectman, J. Wittes (1993)
Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol.The American journal of cardiology, 71 1
-
K. Kozarsky, M. Donahee, A. Rigotti, S. Iqbal, E. Edelman, M. Krieger (1997)
Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levelsNature, 387
-
J. Tardif, J. Grégoire, P. L'allier, R. Ibrahim, J. Lésperance, T. Heinonen, S. Kouz, C. Berry, R. Basser, M. Lavoie, M. Guertin, J. Rodés‐Cabau (2007)
Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial.JAMA, 297 15
-
G. Franceschini, G. Vecchio, G. Gianfranceschi, D. Magani, C. Sirtori (1985)
Apolipoprotein AIMilano. Accelerated binding and dissociation from lipids of a human apolipoprotein variant.The Journal of biological chemistry, 260 30
-
A. Murphy, J. Chin-Dusting, D. Sviridov, K. Woollard (2009)
The anti inflammatory effects of high density lipoproteins.Current medicinal chemistry, 16 6
-
A. Rigotti, B. Trigatti, M. Penman, H. Rayburn, J. Herz, M. Krieger (1997)
A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism.Proceedings of the National Academy of Sciences of the United States of America, 94 23
-
T. Joy, R. Hegele (2008)
The failure of torcetrapib: what have we learned?British Journal of Pharmacology, 154
-
S. Nissen, T. Tsunoda, E. Tuzcu, P. Schoenhagen, C. Cooper, M. Yasin, G. Eaton, M. Lauer, W. Sheldon, C. Grines, S. Halpern, T. Crowe, J. Blankenship, R. Kerensky (2003)
Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial.JAMA, 290 17
-
S. Robins, D. Collins, J. Wittes, V. Papademetriou, P. Deedwania, E. Schaefer, J. Mcnamara, M. Kashyap, J. Hershman, L. Wexler, H. Rubins (2001)
Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial.JAMA, 285 12
-
C. Ericsson, U. Faire, L. Grip, B. Svane, A. Hamsten, J. Nilsson (1996)
Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patientsThe Lancet, 347
-
P. Barter, M. Caulfield, M. Eriksson (2008)
Effects of torcetrapib in patients at high risk for coronary eventsJournal of Vascular Surgery, 47
-
W. Boden (2000)
High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial.The American journal of cardiology, 86 12A
-
M. Rosenblat, M. Aviram (2009)
Paraoxonases role in the prevention of cardiovascular diseasesBioFactors, 35
-
F. Jin, V. Kamanna, Mei-Yu Chuang, K. Morgan, M. Kashyap (1996)
Gemfibrozil stimulates apolipoprotein A-I synthesis and secretion by stabilization of mRNA transcripts in human hepatoblastoma cell line (Hep G2).Arteriosclerosis, thrombosis, and vascular biology, 16 8
- Publisher
- Springer Journals
- Copyright
- Copyright © 2010 by Adis Data Information BV
- Subject
- Medicine & Public Health; Cardiology; Pharmacotherapy; Pharmacology/Toxicology
- ISSN
- 1175-3277
- eISSN
- 1179-187X
- DOI
- 10.2165/11319590-000000000-00000
- pmid
- 20104929
- Publisher site
- See Article on Publisher Site
Abstract
The inverse correlation between high-density lipoprotein (HDL) levels and cardiovascular disease has driven several investigators to target the increase in this lipoprotein to prevent atherosclerosis and its complications. However, many reports have demonstrated that the use of HDL cholesterol (HDL-C) levels as a means to prevent and treat atherosclerosis has mainly resulted in negative outcomes. These findings may help to increase our knowledge of HDL metabolism and its protective effect.
Journal
American Journal of Cardiovascular Drugs – Springer Journals
Published: Aug 17, 2012